Condition: Primary Brain Tumor · Sponsor: Technische Universität Dresden
Brain tumors are the second most frequent malignant diseases in children and adolescents. In the study the short and medium term consequences of proton therapy on cognitive processes in particular on executive functions in pediatric patients shall be highlighted/analysed/evalutated. In a second step, these results are to be compared with 1. a group of children and adolescents who had only /exclusively had operative therapy and 2. with a healthy control group. Thus, the extent to which these treatment options differ in terms of their short and medium-term effect is assessed. Methods of neurocognitive/neurophysiology brain research approaches are applied that may potentially visualize even small / subtle changes in mental activities/neurocognitive function. Therefore the effects of treatment can be evaluated and the neuropsychological outcome of children and adolescents with brain tumors can be improved.
This description comes directly from the study's public registry record.
Mechthild Krause, Prof. Dr. · +49 351 458 2238 · mechthild.krause@uniklinikum-dresden.de
Always discuss trial participation with your own doctor first.
| University Hospital Carl GUstav Carus Dresden, Child and adolescent psychiatry and psychotherapy | Dresden, Saxony, Germany | Recruiting |
| University Hospital Carl GUstav Carus Dresden, Department of Neuropaediatrics | Dresden, Saxony, Germany | Recruiting |
| University Hospital Carl GUstav Carus Dresden, Department of Radiation Therapy and Radiation Oncology | Dresden, Saxony, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04066465